46
Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

Embed Size (px)

Citation preview

Page 1: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

Drug Metabolism and Pharmacogenetics

Brendan Stamper

University of Washington

Dept. of Medicinal Chemistry

Page 2: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

What is Medicinal Chemistry?

• Medicinal Chemistry is a scientific discipline involved with designing, synthesizing and developing pharmaceuticals suitable for therapeutic use

• Highly interdisciplinary science combining genetics, molecular biology, biochemistry, organic chemistry, pharmacology, toxicology

Page 3: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

Outline

• Background– Drug Metabolism– Pharmacogenetics

• Examples– CYP2D6

• Codeine• DDI Scenario (fluoxetine)

– ALDH2• Ethanol• DDI Scenario (acetaminophen)

Page 4: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

Basic Vocabulary

• Lipophilicity vs Hydrophilicity– Lipophile: “Fat-lover”– Hydrophile: “Water-lover”

• Xenobiotic: a foreign chemical substance

Page 5: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

More Basic Vocabulary

• Metabolism: chemical reactions that occur in living organisms

• Enzyme: a biomolecule that catalyzes a chemical reaction

Xenobiotic MetaboliteEnzyme

Inducer

Inhibitor

Page 6: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

Today’s Focus

• We will focus on the enzymatic conversion of lipophilic xenobiotics to more water soluble metabolites . . .

. . . and how these processes are influenced by genetic predisposition

WHY DO WE CARE?

Page 7: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

• Lipophilic xenobiotics can be potentially dangerous because they can easily permeate lipid cell membranes and accumulate within cells

• By converting lipophilic xenobiotics to hydrophilic metabolites we can facilitate elimination

Page 8: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

Today’s Focus

• We will focus on the enzymatic conversion of lipophilic xenobiotics to more water soluble metabolites . . .

. . . and how these processes are influenced by genetic predisposition

(i.e. Can we expect xenobiotic metabolism to be consistent from person-to-person?)

NO

Page 9: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

Variability in Dose-Response “If it were not for the

great variability among individuals, medicine might as well be a science and not an art”

William Osler1849-1919

What factors are responsible for this variability?

Page 10: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

DrugResponse

Age

Gender

Race

DietOccupational

Exposure

Genetics

DiseaseStress

Variability in Dose-Response

Page 11: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

Pharmacogenetics

• Definition: The study of genetic variation that gives rise to variability in drug response (Optimize efficacy and limit toxicity)

DrugResponse

Age

Gender

Race

DietOccupational

Exposure

Genetics

DiseaseStress

Page 12: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

How do we predict optimal dose for most efficacious response

• Step 1: Understand the mechanism of drug action at the molecular level

• Step 2: Understand how genetic variations affect drug action

• Step 3: Rational choice of drug and dosage

Page 13: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

DNA Is Like a Language

• DNA• ATGC• Codon• Gene• Chromosome• Genome

• English• Abcdef . . .• Word• Sentence• Chapter• Book

Like language, DNA changes over time

Page 14: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

Polymorphism• Polymorphism: Change in DNA sequence that occurs in more

than 1% of the population• Allele: An alternative form of a gene (i.e. site of sequence

variation)• SNP (Single Nucleotide Polymorphism)

Gene: ATG-GGA-TGC-TAA met-gly-cys-STOPSNP: ATG-GCA-TGC-TAA met-ala-cys-STOP

• Impact of new allele– Alter protein function– Alter protein structure or stability– No consequence

Page 15: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

CYP2D6 and Codeine

Example #1

Page 16: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

Codeine• Analgesic• Prodrug• CYP2D6-mediated bioactivation critical for

analgesic effect– 200mg codeine is equivalent to 30mg morphine (~10%)

CYP2D6

More Lipophilic More Hydrophilic

Page 17: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

CYP2D6

• Drug metabolizing enzyme

• Member of the P450 family (Cytochrome P450 2D6)

• Common substrates– Beta-blockers (Metoprolol)

– SSRIs (Fluoxetine)

– Opiods (Codeine)

– SERMs (Tamoxifen)

• Highly polymorphic enzyme– Over 100 reported

Rowland et al, JBC (2006) 281:7614-7622

Page 18: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

Allele Kinetic Data

Kinetic plot of product formation versus substrate concentration for metabolic turnover of codeine catalyzed by highly purified recombinant CYP2D6 isoforms in vitro.

Yu et al, JPET (2002) 303:1291-1300

Page 19: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

CYP2D6 Genotypes

1. Ultra Metabolizers

2. Extensive Metabolizers

3. Intermediate Metabolizers

4. Poor Metabolizers

Page 20: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

Poor vs Extensive Metabolizers

Individual plasma concentration of codeine and morphine in 14 extensive (filled) and 14 poor (open) metabolizers after an oral dose of codeine.

Poulsen et al, Eur J Clin Pharmacol (1996) 51:289-295

Page 21: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

How can we sort the population into the different CYP2D6

metabolizing groups?

Page 22: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

Urinary Metabolic Ratio of CYP2D6 Substrate

• Dose patients with CYP2D6 substrate (codeine)

• Collect urine sample that contains substrate and metabolite

• Calculate ratio of substrate over metabolite

Substrate (codeine)

Metabolite (morphine)= High (poor metabolizer)

Low (extensitve metabolizer)

Page 23: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

Roden et al, Ann Intern Med 2006; 145:749-757

Urinary Metabolic Ratio of CYP2D6 Substrate

IntermediateMetabolizers

Page 24: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

Outcomes of CYP2D6 Allelic Variations

Zanger et al, Naunyn-Schiedeberg’s Arch Pharmacol (2004) 369: 23-37

No analgesic effect

Pain relief

‘Overdose’ effect

Slight analgesic effect

Null allele

Decreased function allele

Fully functional allele

Expected plasma concentration-time curve with therepeutic window indicated by the boxed area

Page 25: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

Codeine Pharmacogenetics

Green: Intermediate and Extensive MetabolizersPurple: Ultra MetabolizersOrange: Poor Metabolizers

Page 26: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

Who are most affected by CYP2D6 polymorphisms?

Page 27: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

Ethnic Variation in CYP2D6 Mutation Frequencies

Variant Phenotype Caucasian Asian AfricanEthiopian/

Saudi

CYP2D6*2xN UM 1-5% 0-2% 2% 10-16%

CYP2D6*4 PM 12-21% 1% 2% 1-4%

CYP2D6*10 IM 1-2% 51% 6% 3-9%

CYP2D6*17 IM 0% ND 34% 3-9%

CYP450 allele nomenclature committee database: http://www.imm.ki.se/cypalleles

Page 28: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

DDI Scenario:Codeine and Fluoxetine

+

Page 29: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

Drug-Drug Interactions:Codeine + Fluoxetine

CodeineCYP2D6

Morphine

Fluoxetine(inhibitor)

X

Zanger et al, Naunyn-Schiedeberg’s Arch Pharmacol (2004) 369: 23-37

Page 30: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

Summary: CYP2D6 & Codeine• Codeine is a prodrug (requires metabolism)• CYP2D6 metabolizes codeine to morphine• CYP2D6 is a highly polymorphic enzyme• Populations can be separated into different metabolic

sub-groups– UMs: ‘Overdose’ analgesic effect– EMs/IMs: Predicted analgesic effect– PMs: No analgesic effect

• Urinary sampling can enable the pre-sorting of different metabolizers

• Co-treatment with fluoxetine: EMs to PMs

Page 31: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

ALDH2 and Ethanol

Example #2

Page 32: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

Ethanol

• Low dose: Muscle relaxant, euphoria impaired judgment

• High dose: CNS depressant, impaired sensory/motor function

• Toxic when BAC > 400mg/dL (0.4%)

Page 33: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

Ethanol Metabolism

• Alcohol to aldehyde to carboxylic acid• Ethanol: CNS depressant• Acetaldehyde: Vasodilator

– Flushing– Hangover effects

• Acetic Acid: Relatively harmless

ADH ALDH

More Lipophilic More Hydrophilic

Page 34: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

ALDH2

• Aldehyde dehydrogenase 2• Mitochondrial enzyme• Homotetramer• Substrates: aldehydes• Cofactor: NAD+

• Catalyzes the oxidation of aldehydes

• Polymorphic enzyme

Larson et al, JBC (2005) 280:30550-30556

Page 35: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

ALDH2 Genotypes

• ALDH2*1/*1 Wild-type Homozygous

• ALDH2*1/*2 Heterozygous

• ALDH2*2/*2 Mutant Homozygous

• *2 allele = E487K mutation

Page 36: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

ALDH Crystal

Structure

Violet & Blue: NAD+-bound ALDH2*1Red: NAD+-bound ALDH2*2

Larson et al, JBC (2005) 280:30550-30556

*2 Mutation: E487K

Page 37: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

Kitagawa et al, FEBS Letters (2000) 476:306-311

ALDH2 Activity Among Differing Genotypes

Comparison of substrate specific activities of human liver ALDH2 derived from three ALDH genotypes

MALD

AALD

BALD

PALD

Page 38: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

ALDH2 Influence on AALD Blood Levels Following Ethanol Ingestion

Ginsberg et al, Reg Toxicol Pharmacol (2002) 36, 297-309

ADH ALDH2*1/*1

No FlushingNo Hangover Effects

Some FlushingSome Hangover Effects

FlushingHangover Effects

ALDH2*1/*2ALDH2*2/*2

X

X

X

Page 39: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

Who is Affected?

Ginsberg et al, Reg Toxicol Pharmacol (2002) 36, 297-309

ALDH2 polymorphism by ethnic group

Page 40: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

How do you treat an acetaldehyde overdose?

Page 41: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

DDI Scenario:(Ethanol and Acetaminophen)

+

Analgesic/AntpyreticCNS Depressant

Page 42: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

Drug-Drug Interaction:Ethanol and Acetaminophen

CYP2E1

Glutathione adducts(Detoxification)

Protein adducts(Toxicity)Ethanol

(inducer)

X

Cell Death

Liver Damage

NAPQI

Page 43: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

Toxic Scenario1. Chronic alcohol abuser induces CYP2E1

2. ‘Activated’ CYP2E1 forms more toxic metabolite (NAPQI)

3. Increased levels of NAPQI can lead to glutathione depletion

4. Increased protein adduct formation leading to cell death and liver damage

If a you are a chronic alcohol abuser, use ibuprofen instead of acetaminophen to treat your hangover.

Page 44: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

Summary: ALDH2 & Ethanol

• Ethanol metabolism occurs in two steps– ADH: Ethanol to acetaldehyde (toxic metabolite)– ALDH2: Acetaldehyde to acetic acid (detoxification step)

• Three common ALDH2 genotypes– ALDH2*1/*1: No flushing or hangover effects– ALDH2*1/*2: Some flushing and hangover effects– ALDH2*2/*2: Flushing and hangover effects

• ALDH2*2 most prevalent in Asian populations• Chronic alcohol abusers should not take

acetaminophen to treat their hangovers

Page 45: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

Things to Think About• Drug metabolizing enzymes tend to metabolize lipophilic compounds

into hydrophilic compounds (absorption to excretion)• Your genotype impacts how you metabolize drugs• Pharmacogenetics can be used to optimize therapy• Science is interdisciplinary

Genetics - Molecular Biology - Biochemistry - Organic Chemistry - Pharmacology - Toxicology

Page 46: Drug Metabolism and Pharmacogenetics Brendan Stamper University of Washington Dept. of Medicinal Chemistry

Thank you!